U.S. Sees Dramatic Drop in Routine Testing Amid Pandemic
A new report from Komodo Health shows that diagnostic testing for cancer and other conditions has declined across the U.S. since mid-March following regional lockdowns for the COVID-19 pandemic. Komodo Health analyzed billing records of 320 million patients from March 19 through April 20 and found that cervical cancer screenings have dropped by 68 percent, cholesterol tests have fallen by 67 percent, and diabetes detection testing was down 65 percent nationally. The greatest reductions happened in areas that have been particularly hard-hit by the pandemic. A1c tests,...